Experienced in Alpha-1 Antitrypsin Deficiency (AATD)

Dr. Joel A. Wirth

South Portland, ME
Experienced
in Alpha-1 Antitrypsin Deficiency (AATD)
Specialties:Pulmonary Medicine
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Joel Wirth is a Pulmonary Medicine provider in South Portland, Maine. Dr. Wirth and is rated as an Experienced provider by MediFind in the treatment of Alpha-1 Antitrypsin Deficiency (AATD). His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Lung Metastases, and Bronchiectasis. Dr. Wirth is currently accepting new patients.

His clinical research consists of co-authoring 7 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pulmonary Medicine
Licenses
Internal Medicine in ME
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Anthem
  •  Humana

Locations

100 Foden Road, West Building Suite 103, South Portland, ME 04106
207-828-1122

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: February 06, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Completed
Publish Date: February 05, 2024
Intervention Type: Drug
Study Phase: Phase 2
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
Enrollment Status: Unknown
Publish Date: August 04, 2023
Intervention Type: Drug
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

7 Total Publications

Ceftriaxone to PRevent pneumOnia and inflammaTion aftEr Cardiac arresT (PROTECT): study protocol for a randomized, placebo-controlled trial.
Ceftriaxone to PRevent pneumOnia and inflammaTion aftEr Cardiac arresT (PROTECT): study protocol for a randomized, placebo-controlled trial.
Journal: Trials
Published: August 10, 2021
Similar Doctors
Expertise in
32
conditions
Dr. Neil J. Duval
Pulmonary Medicine
Expertise in
32
conditions
Dr. Neil J. Duval
Pulmonary Medicine

Central Maine Medical Center

300 Main St, 
Lewiston, ME 
 (32.6 mi)
207-753-3900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Neil Duval is a Pulmonary Medicine provider in Lewiston, Maine. Dr. Duval and is rated as a Distinguished provider by MediFind in the treatment of Alpha-1 Antitrypsin Deficiency (AATD). His top areas of expertise are Asthma in Children, Asthma, Grass Allergy, and Lung Metastases. Dr. Duval is currently accepting new patients.

Expertise in
2
conditions
Dr. M E. Knauft
Pulmonary Medicine
Expertise in
2
conditions
Dr. M E. Knauft
Pulmonary Medicine

Chest Medicine Associates PA

100 Foden Rd, Suite 103, 
South Portland, ME 
 (0.1 mi)
207-828-1122
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

M Knauft is a Pulmonary Medicine provider in South Portland, Maine. Dr. Knauft and is rated as an Advanced provider by MediFind in the treatment of Alpha-1 Antitrypsin Deficiency (AATD). Her top areas of expertise are Cystic Fibrosis, Alpha-1 Antitrypsin Deficiency (AATD), Emphysema, and Lung Metastases. Dr. Knauft is currently accepting new patients.

Expertise in
19
conditions
Dr. Paul J. Laprad
Pulmonary Medicine | Intensive Care Medicine
Expertise in
19
conditions
Dr. Paul J. Laprad
Pulmonary Medicine | Intensive Care Medicine
121 Medical Center Drive, Suite 3300, 
Brunswick, ME 
 (28.7 mi)
207-373-6490
Languages Spoken:
English

Paul Laprad is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Brunswick, Maine. Dr. Laprad and is rated as a Distinguished provider by MediFind in the treatment of Alpha-1 Antitrypsin Deficiency (AATD). His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Asthma in Children, and Asthma.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile